Document is current
Any future updates will be listed below
-
Authors
Mendivil, Joan
Zhu, Li
Bonner, Nicola
Gargon, Elizabeth
Jouvin, Marie-Helene
Abetz-Webb, Linda
Fairbanks, Hannah
Sims, Joel
Middlehurst, Jessica
Cronin, Patrick
Chen, Maggie
Cohn, Danny M.
Lu, Peng
Riedl, Marc A.
-
Funding
Funding for this research was provided by:
Pharvaris Netherlands B.V.
Adelphi Values
- License Information
-
More Information
Article History
Received: 22 August 2025
Accepted: 27 December 2025
First Online: 2 March 2026
Declarations
:
: was obtained from Western Copernicus Group Independent Review Board (IRB number: 20225798) prior to the conduct of any study activities. All participants provided written informed consent after being provided with full information about the study. This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, consistent with regulatory requirements.
: JMe is an employee of Pharvaris GmbH. LZ, MC, and PL are employees of Pharvaris Inc. NB, EG, HF, JS, JMi, and PC are employees of Adelphi Values, which received funding for this study from Pharvaris Inc. M-HJ was an employee of Pharvaris Inc. at the time that the study was conducted. LA-W has received consultancy fees from Pharvaris and Takeda. DMC has received consultancy fees from Astria, BioCryst, CSL Behring, Ionis, Intellia, KalVista, Otsuka, Pharvaris, Takeda; speaking fees from CSL Behring, Ionis, Takeda. MAR has received research grant support, consultancy fees, speaker fees, and/or clinical trial fees from Astria, BioCryst, BioMarin, Celldex, CSL Behring, Cycle Pharma, Grifols, Intellia, Ionis, KalVista, Novartis, Pharming, Pharvaris, Sanofi-Regeneron, Takeda.
